Previous studies reported the correlation of CD11b and poor clinical outcomes in some type of cancers, as well as its therapeutic potential (Ahn et al., 2010; Chen et al., 2013; Ochoa et al., 2007; Sabbatino et al., 2018; Xu et al., 2016). This evidence concerns the gene ITGAM and cancer.